{"entity":{"id":"inv-1120","kind":"drug","name":"INV-1120","aka":[],"tldr":"INV-1120 is an experimental EP4 antagonist from Shenzhen Ionova Life Sciences, in phase 1 trials for advanced solid tumours.","summary":"INV-1120 is an EP4 antagonist from Shenzhen Ionova Life Sciences. An EP4 inhibitor (antagonist) tested alone and with pembrolizumab in advanced solid tumours. Its furthest stage is phase 1, for advanced solid tumours. ClinicalTrials.gov registers it in one study linked below. Registry status RECRUITING (phase 1) on 3 Nov 2026; the company's latest INV-1120 news is from Nov 2022. Whether it works in people has not been established unless a trial below reports it.","status":"phase-1","asOf":"2026-11-03","links":[{"label":"Shenzhen Ionova Life Sciences: ionovabio.com","url":"https://www.ionovabio.com/en/companynews"},{"label":"Shenzhen Ionova Life Sciences: ionovabio.com","url":"https://www.ionovabio.com/companynews"},{"label":"Shenzhen Ionova Life Sciences: clinicaltrials.gov","url":"https://clinicaltrials.gov/api/v2/studies/NCT04443088"},{"label":"ClinicalTrials.gov: trials of INV-1120","url":"https://clinicaltrials.gov/search?intr=INV-1120"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["metastatic-cancer"],"sections":[],"technologies":[],"targets":["ep4"],"drugs":[],"companies":["shenzhen-ionova-life-sciences"],"institutions":[],"pathways":[],"terms":[],"trials":["nct04443088"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"provenance":{"editedBy":"OnCo gap audit, class 5 (company pipeline pages and ClinicalTrials.gov v2)","editedOn":"2026-11-03"},"code":"INV-1120","modality":"EP4 antagonist","mechanism":"An EP4 inhibitor (antagonist) tested alone and with pembrolizumab in advanced solid tumours.","approvals":[],"mechanismSteps":[],"toxicity":[],"access":[],"regulatoryEvents":[]},"route":"/drugs/inv-1120/","neighbours":{"cancer":[{"id":"metastatic-cancer","kind":"cancer","name":"Metastatic cancer (cancer that has spread)","route":"/cancers/metastatic-cancer/"}],"target":[{"id":"ep4","kind":"target","name":"EP4 (PTGER4)","route":"/targets/ep4/"}],"company":[{"id":"shenzhen-ionova-life-sciences","kind":"company","name":"Shenzhen Ionova Life Sciences","route":"/companies/shenzhen-ionova-life-sciences/"}],"trial":[{"id":"nct04443088","kind":"trial","name":"An Open-Label Study of INV-1120 as a Single Agent and in Combination With Pembrolizumab in Adult Patients With Advanced Solid Tumors","route":"/trials/nct04443088/"}]}}